Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Han has performed speaking for Boehringer Ingelheim GmbH; Pfizer, Inc; and GlaxoSmithKline. She has also consulted for Novartis AG; Genentech, Inc; GlaxoSmithKline; Pfizer, Inc; Boehringer Ingelheim GmbH; and MedImmune LLC. Dr Martinez has participated in advisory boards in COPD development for GlaxoSmithKline; MedImmune LLC; AstraZeneca; Merck & Co, Inc; Perl; Novartis AG; Forest Laboratories, Inc/Almirall, SA; Takeda Pharmaceuticals International GmbH; Schering-Plough Corp; Hoffmann-La Roche Inc; Bayer; Actelion Pharmaceuticals Ltd; Pfizer, Inc; Talecris; Health Learning Systems; Comgenix; FBCommunications; BoomComm; and Ikaria, Inc. He has been a member of a steering committee for COPD studies sponsored by GlaxoSmithKline, Actelion Pharmaceuticals Ltd, MPex, and Takeda Pharmaceuticals International GmbH. He has participated in US Food and Drug Administration mock panels for Boehringer Ingelheim GmbH and Forest Laboratories, Inc. He has been a member of advisory boards for IPF drug development for Elan Corp, plc; Quark; Genzyme Corp; Takeda Pharmaceuticals International GmbH; and Ikaria, Inc. He has been a member of steering committees for IPF studies sponsored by Actelion Pharmaceuticals, Ltd; Genzyme Corp; Gilead; and Johnson & Johnson/Janssen Biotech, Inc. The University of Michigan received funds from Boehringer Ingelheim GmbH for COPD study and from Actelion Pharmaceuticals Ltd for IPF study. Dr Martinez has served on speaker’s bureaus or in continuing medical education activities sponsored by GlaxoSmithKline; NACE; Med-Ed; Potomac; Pfizer, Inc; Boehringer Ingelheim GmbH; Schering-Plough Corp; Vox Medica, Inc; American Lung Association; WebMD; Epocrates; AstraZeneca; France Foundation; Altana Pharma/Nycomed; and UpToDate. He has received royalties from Associates in Medical Marketing and Castle Connolly. Dr Sciurba has received research funds from the National Institutes of Health; GlaxoSmithKline; Pfizer, Inc; Boehringer Ingelheim GmbH; and Forest Laboratories, Inc. He has also received consulting funds from GlaxoSmithKline, AstraZeneca, and PneumRx. Dr Wise has served as a consultant for AstraZeneca; Boehringer Ingelheim GmbH; GlaxoSmithKline; InterMune; Merck & Co, Inc; MedImmune LLC; Novartis AG; Pfizer, Inc; Sunovion Pharmaceuticals, Inc; and Spiration, Inc. He has received research grants from Boehringer-Ingelheim GmbH; Forest Laboratories, Inc; and GlaxoSmithKline. Drs Berry, Drummond, Limper, and Schwarz and Mss Li and Fuller have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.